What Is MACE in GLP-1 Cardiovascular Trials? A 2026 Plain-English Decoder

Quick-reference: MACE terminology

What is MACE in GLP-1 cardiovascular trials?

MACE — Major Adverse Cardiovascular Events — is a single trial number that counts whether participants had any of several severe heart-related events during the study. It is a composite endpoint, meaning several different outcomes get combined into one count. Most GLP-1 cardiovascular trials count three events: cardiovascular death, non-fatal myocardial infarction (a heart attack the person survived), and non-fatal stroke.

Here is the part most pages skip. MACE is not a diagnosis. Your doctor will not tell you that you "have MACE." MACE is a measurement tool used in research. Trials use it because heart attacks, strokes, and cardiovascular deaths are related but separate. Adding them together gives the trial enough events to find a real difference between groups within a few years instead of needing decades.

The three components in classic 3-point MACE

When you read "Wegovy reduced MACE by 20%" or "Rybelsus reduced MACE by 14%," that single number is doing a lot of work. It is combining three events into one figure. Whether that 20% applies to you depends on which three events the trial counted, who was in the trial, and how large your starting risk is.

3-point vs. 4-point vs. 5-point MACE — why the difference matters

Most GLP-1 trials use 3-point MACE, but a few add extra events to the count. The wider the composite, the more events the trial sees, but the harder it gets to know exactly what the drug helped. The first thing to check in any new MACE headline is which composite the trial used.

Major GLP-1 and incretin-related trials that measured MACE

The master decoder matrix · 14 trials · Sources linked per row · Verified May 18, 2026

Fourteen GLP-1 or incretin-related cardiovascular, kidney, diabetes, and obesity outcome trials are included here because they measured, reported, or are designed to test MACE-style endpoints. Seven showed a statistically significant reduction in a primary 3-point MACE endpoint versus placebo. FLOW showed a significant secondary 3-point MACE result with a kidney-primary endpoint. ELIXA, EXSCEL, and PIONEER 6 demonstrated cardiovascular safety without primary superiority. SURPASS-CVOT and ACHIEVE-4 used active comparators.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1. It activates two hormone receptors instead of one. We include it in this matrix because it is part of the same conversation, but its trial design and pharmacology differ from the pure GLP-1 drugs above it.

What a "20% MACE reduction" actually means for one person

A "20% MACE reduction" is a relative risk reduction. It does not mean 20 out of every 100 people avoided a heart attack. In SELECT, the 20% relative reduction translated to an absolute event-rate drop from 8.0% to 6.5% over about 3.3 years — a 1.5 percentage-point difference. Translated to a crude number-needed-to-treat: roughly 67 people with obesity and heart disease had to take Wegovy for about 3 years to prevent one additional MACE event.

Relative vs. absolute — the difference that changes everything

Crude NNT estimates from each major GLP-1 MACE trial

Which GLP-1 drugs are FDA-approved to reduce MACE today

As of May 2026, five GLP-1 brand families carry FDA-labeled MACE or cardiovascular risk-reduction language: Victoza, Ozempic (injection and tablets), Trulicity, Wegovy (injection and tablets), and Rybelsus. Tirzepatide (Mounjaro / Zepbound) does not currently have an FDA cardiovascular indication. Foundayo (orforglipron) is currently approved for chronic weight management only.

Why MACE results vary across GLP-1 trials

MACE results across GLP-1 trials range from neutral (ELIXA, EXSCEL) to a 27% reduction (AMPLITUDE-O). The variation is not random. It reflects four real differences between trials: the patient population, the exact MACE composite used, the comparator (placebo vs. active drug), and the trial's follow-up duration.

Why MACE usually does NOT include heart failure or kidney problems

Classic 3-point MACE does not count heart failure hospitalizations, kidney function decline, atrial fibrillation, blood pressure changes, cholesterol changes, or quality of life. These are separate endpoints, often measured separately in the same trial. A drug can affect MACE strongly and heart failure weakly — or the other way around.

This trips people up. Someone reads "Wegovy reduces MACE" and assumes that means Wegovy prevents every heart problem. It does not. The MACE label specifically refers to three events: cardiovascular death, non-fatal heart attack, non-fatal stroke. Heart failure and kidney outcomes are separate questions.

Where heart failure and kidney outcomes show up in GLP-1 trials

• FLOW (semaglutide) — kidney-specific composite as the primary endpoint. The January 2025 Ozempic label expansion is for kidney disease progression and cardiovascular death in T2D + CKD. That CKD indication is separate from the 3-point MACE indication.
• SUSTAIN-6 — heart failure hospitalization was a secondary outcome (not significantly reduced as a standalone).
• AMPLITUDE-O and Harmony Outcomes — both showed reductions in heart failure hospitalizations as secondary outcomes.
• SURMOUNT-MMO (pending) — heart failure events are part of the 5-point primary composite.

If you care about heart failure or kidney protection specifically, do not stop at the MACE number. Check whether the trial reported those endpoints separately and what they showed.

The 5 biggest mistakes people make reading GLP-1 MACE headlines

The most common errors are: confusing relative risk with absolute risk, assuming all MACE definitions are the same, ignoring the trial population, treating active-comparator trials like placebo trials, and applying group results as personal prescriptions. Avoiding these five mistakes lets you read any GLP-1 cardiovascular headline correctly.

How to decode any GLP-1 MACE claim — the 7-question checker

Before trusting any "% MACE reduction" headline, run it through these seven questions. If you can answer all seven, you can interpret the claim correctly. If you cannot, the headline is incomplete.

1. 1

   Which trial is the claim from?

   Name it. If you cannot name it, the source is incomplete.

2. 2

   Who was in the trial?

   T2D? Obesity? Established CVD? Recent acute coronary syndrome? CKD?

3. 3

   What was the comparator?

   Placebo, or another active drug?

4. 4

   What exactly counted as MACE?

   3-point? 4-point? Kidney-primary composite?

5. 5

   Was the result superior or just non-inferior?

   "Non-inferior" means "as good as," not "better than."

6. 6

   What were the absolute event rates?

   Not just the percentage reduction — the actual percentages in each group.

7. 7

   Does the current FDA label support the claim for this person?

   A trial result and a label indication are not the same thing.

Bad-claim vs. better-claim examples

What this means if you are…

The right way to read these trials depends on who you are. Below are the trials and labels most relevant to specific reader situations.

Why every GLP-1 has a cardiovascular trial — the FDA backstory

In December 2008, the FDA required every new type 2 diabetes drug to prove it did not increase cardiovascular risk. This requirement drove the design of ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6, and AMPLITUDE-O. In March 2020, the FDA replaced the mandate with a more flexible safety framework, because the previous 12 years of trials had found no unexpected harm — and several had shown benefit.

The history matters because it explains why we have so much cardiovascular data on GLP-1s in the first place.

In the early 2000s, the diabetes drug rosiglitazone faced a serious cardiovascular safety controversy. A meta-analysis raised concerns about heart attack risk. The FDA responded in 2008 with new guidance: any new diabetes drug had to demonstrate, through a dedicated cardiovascular outcomes trial, that it did not increase MACE by more than 30% versus placebo. To meet that bar with statistical confidence, drug makers had to run trials with thousands of patients followed for years. That mandate is the reason we have rich cardiovascular outcomes data for nearly every modern GLP-1.

Between 2008 and 2020, fifteen diabetes drug cardiovascular outcomes trials were completed. None showed increased cardiovascular risk. Several showed benefit. In March 2020, the FDA issued new draft guidance replacing the one-size-fits-all mandate with a more flexible approach — case-by-case cardiovascular safety review based on pre-marketing data, with post-marketing surveillance scaled to the drug's specific signal. See the ACC summary of the 2020 FDA guidance.

Trials continue today (SOUL, SURPASS-CVOT, ACHIEVE-4, SURMOUNT-MMO) — but they are run primarily to establish cardiovascular indications for marketing approval, not to satisfy a baseline safety requirement.

Honest limitations of MACE as an endpoint

MACE is a useful research tool but it has three known problems: it treats different events as equally important, its definition varies between trials, and a "positive" trial result can sometimes be driven by softer events. Recognizing these limits helps you read any cardiovascular trial more carefully.

What's coming next — trials to watch

Three major GLP-1 cardiovascular developments are pending publication, regulatory review, or readout. Each could expand the cardiovascular label landscape over the next 12–24 months.

We will update this page whenever any of these read out or receive an FDA decision.

Does MACE evidence affect insurance coverage?

A GLP-1 cardiovascular indication can change how an insurance plan evaluates your prescription, especially for plans that exclude weight-loss-only medications. But cardiovascular evidence does not guarantee coverage — it just opens an additional path.

Many commercial and Medicare plans cover GLP-1s for diabetes more readily than for weight loss. When a GLP-1 has an FDA cardiovascular indication, payers sometimes approve coverage based on the cardiovascular diagnosis (established CVD, T2D + cardiovascular risk factors, CKD) instead of, or in addition to, the weight-loss indication.

Wegovy's March 2024 cardiovascular indication gave some patients a coverage pathway through their cardiovascular diagnosis when their plan did not cover weight loss. Ozempic's January 2025 expansion for T2D + CKD opens similar coverage routes for that population.

Coverage documentation checklist by FDA-label pathway

A starting point for the documentation a prior authorization request typically asks for. Your plan may require more or different items.

Methodology — how we built this page

What we verified (May 18, 2026)

• Every primary MACE endpoint definition in the master matrix was checked against the original trial publication in NEJM, Lancet, JAMA, or Circulation.
• Every event rate and hazard ratio was checked against the primary publication, with secondary verification against the ACC, EASD, or ADA trial summary.
• Every FDA cardiovascular indication was checked against the current prescribing information on DailyMed or accessdata.fda.gov.
• Where a trial was presented but full publication is still pending (currently ACHIEVE-4), we used the official late-breaking session presentation and the manufacturer's investor release, and we labeled that uncertainty clearly in the table.

Source hierarchy

What we did not do

• · We did not invent any numbers.
• · We did not run a patient-level or statistical reanalysis. We did calculate crude absolute risk reductions and approximate NNTs from published event rates, and we label those clearly.
• · We did not make up an author or use the phrase "medically reviewed by." This page reflects the editorial team's research synthesis, not a clinician's review.
• · We did not rank drugs by "best for the heart." Every drug's data depends on the population studied.
• · We did not provide personalized medical advice.
• · We did not include post hoc subgroup analyses as if they were primary findings.

How often we re-verify

Quarterly minimum, with triggered updates on any new FDA cardiovascular indication, any new GLP-1 cardiovascular trial publication, or any change to the prescribing information of a GLP-1 currently on this page. For a broader walkthrough of how to read these trials yourself, see our research section.

Frequently asked questions about MACE in GLP-1 trials